ASNC has confirmed reports that supply disruptions with both Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP) may take place after January 2026. These products are used in the diagnosis of cardiac amyloidosis.
ASNC is in contact with the manufacturers of both products to understand the extent of the shortages and the projected timelines for resuming production.
ASNC will share updates as this issue evolves. To be among the first to receive email alerts with breaking news, be sure to keep your ASNC membership current.
Article Type
News & Announcements
Category
Advocacy
Related Posts
ASNC Leader Appointed to U.S. Preventive Services Task Force
Venkatesh Murthy, MD, PhD, MASNC, has been appointed to the U.S. Preventive…
2027 HOPPS Proposed Rule Would Restructure Nuclear Medicine APCs, Could Affect Nuclear Cardiology Payment Rates
In the 2027 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule, the…
Check Now! Are You on CMS’s Heart Failure Payment Model List?
“ASNC Members, it is critically important that you check the CMS website…

